Background Some studies suggest that patients with asthma who are homozygous for arginine at the 16th aminoacid position of the β 2 -adrenergic receptor (B16 Arg/Arg) benefi t less from treatment with longacting β 2 agonists and inhaled corticosteroids than do those homozygous for glycine (B16 Gly/Gly). We investigated whether there is a genotype-specifi c response to treatment with a longacting β 2 agonist in combination with inhaled corticosteroid.
Introduction
Combination therapy with longacting β 2 agonists and inhaled corticosteroids is one of the most widely prescribed treatments for the control of asthma in the world. Some studies suggest that, on average, this combination improves lung function and asthma control; 1 others suggest that a subpopulation of patients with asthma could be at risk for severe exacerbations or death with use of longacting β 2 agonists. 2, 3 β 2 agonists act primarily at the β 2 -adrenergic receptor (ADRB2). A common single nucleotide polymorphism in the coding region of ADRB2 codes for arginine instead of glycine at the 16th aminoacid of the receptor (allele frequency 0·4 in white people 4 ). In retrospective and prospective studies in patients with asthma not taking inhaled corticosteroids, regular use of shortacting β 2 agonists, such as salbutamol (albuterol), was associated with lower lung function in individuals homozygous for arginine at the 16th aminoacid position (B16 Arg/Arg) than in individuals homozygous for glycine at that position (B16 Gly/Gly). 5, 6 Another study showed increased risk of exacerbations with regular use of salbutamol but not salmeterol in patients with the B16 Arg/Arg genotype. 7 In view of these genotype-specifi c fi ndings, we undertook a genotype-stratifi ed retrospective analysis of patients with asthma who had participated in randomised trials of the longacting β 2 agonist salmeterol. 8 Patients with the B16 Arg/Arg genotype did not benefi t from treatment with salmeterol, even when used with a concomitant inhaled corticosteroid. We have therefore examined prospectively whether there is a genotypespecifi c diff erence in the response to longacting β 2 agonists, by undertaking a randomised controlled trial that compared the eff ects of salmeterol plus inhaled corticosteroid with inhaled corticosteroid alone in B16 Arg/Arg patients with asthma versus B16 Gly/Gly patients with asthma.
Methods

Participants
Seven centres recruited participants for the LARGE trial. Patients with asthma were recruited from the clinical practices of each study site and through community advertising by use of a variety of media. After patients had given written informed consent (approved by participating site institutional review boards), their medical history was reviewed (eg, medication use and history of asthma exacerbations) and they were screened for eligibility on the basis of the inclusion and exclusion criteria shown in the panel. Blood samples were also taken. B16 genotyping by restriction fragment length polymorphism was confi rmed by sequencing (see webappendix p 1 for details of genotyping). The study protocol was reviewed and approved by an independent protocol review committee appointed by the study sponsor. A separate data and safety monitoring board, also appointed by the sponsor, oversaw the study and reviewed adverse events as the trial was implemented. Figure 1 shows the study design. Arg/Arg and Gly/Gly individuals who met the study criteria entered a pool of eligible patients waiting to be matched with a participant with the opposite genotype, stratifi ed by forced expiratory volume in 1 s (FEV 1 ) and ethnic origin. Individuals with the Arg/Gly genotype were excluded because outcomes for such patients had been inconsistent in previous studies and preliminary data with both shortacting and longacting β 2 agonists were based on diff erences between individuals with Arg/Arg and Gly/Gly genotypes. Match-eligible participants began treatment with open-label, inhaled corticosteroid (hydrofl uoroalkane beclometasone dipropionate [QVAR, Teva, Petach Tikva, Israel] 240 μg twice a day) and salbutamol (as needed), and returned after 3 weeks of treatment for spirometry to establish baseline FEV 1 for matching. Participants returned every 4 weeks thereafter for diary review, medication compliance review, spirometry, and safety checks until a match was identifi ed. Pairs of matched participants (ie, an Arg/Arg and a Gly/Gly participant within 10% of predicted FEV 1 and of the same ethnic origin [white or non-white]) returned to enter the main study.
Matched participants entered an 8-week run-in period to wash out previous use of longacting β 2 agonist (which, in previous studies, was seen to last as long as 8 weeks 7 ). During this run-in period, participants continued treatment with open-label hydrofl uoroalkane beclometasone (240 μg twice a day). Inhaled salbutamol was used
Panel: Inclusion and exclusion criteria
Screening inclusion criteria • Male and female patients, aged 18 years or older • Ability to provide written informed consent • Clinical history consistent with asthma • FEV 1 40% or more of predicted or 50% or more of predicted for patients regularly using inhaled corticosteroids • If on inhaled steroids, patients must have been on a stable dose for at least 2 weeks • Genotype B16 Arg/Arg or B16 Gly/Gly • Reversible airway obstruction (≥12% and 200 mL improvement in FEV 1 after two puff s of inhaled salbutamol) or bronchial hyperresponsiveness with methacholine (20% reduction in FEV 1 [PC 20 ] in response to a concentration of inhaled methacholine ≤8 mg/mL, or PC 20 ≤16 mg/mL if on inhaled corticosteroids) • Non-smoker (total lifetime smoking history <10 pack-years; no more than fi ve occasions of smoking in the past year; no smoking or use of smokeless tobacco in the previous 30 days)
Exclusion criteria
• Use of greater than the equivalent of 1000 μg inhaled fl uticasone daily • Chronic use of any medication other than β agonists or inhaled corticosteroids, except as designated by protocol • Lung disease other than asthma • Established or suspected diagnosis of vocal cord dysfunction • Signifi cant medical illness (other than asthma) that is not stable • History of respiratory tract infection within the previous 6 weeks • History of a signifi cant exacerbation of asthma in the previous 6 weeks • History of life-threatening asthma requiring treatment with intubation and mechanical ventilation within the past 10 years • Hyposensitisation therapy other than an established maintenance regimen • Pregnancy or lactation. If potentially able to bear children, not using an acceptable form of birth control • Patients who were randomised in the BAGS trial, 9 BARGE trial, 5 SOCS trial, 10 or SLIC trial 11 • History of hypersensitivity to soya lecithin or related food products such as soya beans or peanuts FEV 1 =forced expiratory volume in 1 s.
See Online for webappendix as rescue therapy. Asthma control was monitored by peak expiratory fl ow (PEF) via an electronic peak fl ow meter (AM1 device, Cardinal Health, Yorba Linda, CA, USA), and by spirometric values, morning/evening peak fl ow variability index, asthma symptoms, and use of rescue therapy. Baseline data were obtained for airway responsiveness (20% reduction in FEV 1 [PC 20 ] in response to methacholine), bronchodilator response to ipratropium, bronchodilator response to salbutamol, exhaled nitric oxide concentration, and pH in exhaled breath condensate.
Randomisation and masking
Individuals in a matched pair were randomly assigned to the same crossover treatment sequence. Randomisation was done by a password-protected, web-based scheme administered by the Asthma Clinical Research Network (ACRN) Data Coordinating Center. A statistician (SJK) at the data coordinating centre wrote the randomisation program in SAS version 9.1. This code was passed to an unmasked database programmer who assigned a new random number generator seed, assigned blinding codes to each of the treatments (ie, placebo or salmeterol), and ran the program to generate the randomisation codes used in the study. The resulting randomisation list was imported into the study database and accessed by the clinic coordinators via a web-based application. The application returned only a drug kit number from which all study drugs were dispensed for the participant who had been randomised. SJK did not have access to the blinding codes during study implementation or analysis. The database programmer was not involved in the rest of the trial other than to provide routine maintenance of the LARGE database. Clinic personnel, participants, and most data centre personnel (apart from the database programmer and administrative coordinator) remained masked throughout study implementation. Investigators under taking the data analyses were masked to both genotype and treatment allocation. Success of masking was assessed via questionnaires completed by parti cipants and coordinators every time a participant completed a treatment period. Participants were asked for their guess as to which treatment they had just completed, as well as for any specifi c sensations they had noted with the study drug (taste, smell, etc). Coordinators were asked for their guess as to which treatment the participant had just completed.
Procedures
In each treatment sequence, there was an 18-week double-blind treatment phase in which participants received either inhaled longacting β 2 agonist (salmeterol 50 μg twice a day; Serevent 50 μg Diskus, GSK, North Carolina, USA) or matching placebo. Additionally, all participants received open-label, inhaled hydrofl uoroalkane beclometasone (240 μg twice a day). Inhaled ipratropium bromide (two actuations [puff s] as needed; Atrovent, Boehringer Ingelheim, Ridgefi eld, CT, USA) was used as primary rescue therapy to avoid the confounding eff ects of β 2 -adrenergic stimulation on outcome variables. However, if an episode of adverse asthma control responded incompletely to ipratropium, salbutamol was used as a superseding rescue therapy. Patients received the alternative double-blind treatment for the second treatment period.
At the end of each double-blind treatment period, all participants resumed regular use of hydrofl uoroalkane beclometasone, with salbutamol (as needed), for a runout period (fi gure 1). During the two treatment periods and two run-out periods, asthma control was monitored by the same indicators as in the run-in stage. Although the second run-out period lasted 10 weeks (as opposed to 8 weeks for the fi rst run-out period) to assess whether any potential genotype-specifi c eff ects would be seen up to 10 weeks, run-out measurements were taken at the 
Figure 1: Schematic diagram of the trial protocol
After screening and genotyping, genotype-eligible and matched participants who received 8 weeks of inhaled corticosteroid (ICS; hydrofl uoroalkane beclometasone dipropionate 240 μg twice a day) during the run-in period were randomly assigned to continue ICS with either salmeterol or placebo for 18 weeks, followed by an 8-week run-out period on ICS alone, followed by the alternative treatment and a 10-week run-out period. prn=as needed.
end of 8 weeks and compared with the end of the fi rst 8-week run-out period.
Participant adherence with medication dosing was determined by use of a DOSER device (Meditrack Products; Hudson, MA, USA) attached to each beclometasone metered-dose inhaler (MDI). This device registers each actuation of the MDI and stores a daily history, which was reviewed at each clinic visit. Diskus inhalation counters were used to determine the number of inhalations of salmeterol or placebo. These two devices gave objective measurements of the number of puff s or doses actuated.
Diary cards, on which participants recorded the number of puff s of each drug per day, were used as a secondary source of compliance information. These data were compared with PEF measurements electronically recorded and date/time stamped from the electronic peak fl ow meter device. Because participants were instructed to take their morning and evening PEF measurements immediately before taking their study drugs, timing of PEF monitoring was used as a surrogate for timing of dosing with study drugs.
The primary endpoint of the study, assessed separately within and between genotypes, was morning PEF at the end of 18-week treatment. Secondary endpoints included evening PEF, peak fl ow variability ([evening PEFmorning PEF]/evening PEF), FEV 1 , airway responsiveness (methacholine PC 20 ), bronchodilator reversibility with four puff s of either ipratropium or salbutamol, exhaled nitric oxide concentration, and pH in exhaled breath condensate, as described elsewhere. 12 Genotypespecifi c outcomes were examined after stratifi cation by sex and ethnic origin. The asthma control variables analysed were mean daily symptom scores (measured on a scale from 0 [absent] to 3 [severe]), number of actuations of rescue MDI (ipratropium, salbutamol, and the combined total during treatment periods), number of exacerbations, and episodes of adverse asthma control. Variables measured daily from the participant diary cards-eg, PEF and PEF variability were averaged between visits and weighted by the inverse of the squared SE. The purpose of the weighting scheme for diary card data was to assign greater weight to means measured with low variability and less weight to means measured with high variability.
Statistical analysis
With the SD of the primary comparison of interest (ie, comparing the estimate at the end of the placebo treatment period with the estimate at the end of the salmeterol treatment period) with respect to morning PEF from the ACRN BARGE trial (24 L/min), 6 we calculated that a sample size of 24 participants per genotype was required to detect a diff erence of 25 L/min between Arg/Arg and Gly/Gly with a two-sided, 0·05 signifi cance level test, 90% statistical power, and accounting for a 15% dropout rate. However, to attain 1 , a sample size of 40 participants per genotype (80 total randomised participants) was required for an eff ect size of 0·15 L with an estimated SD of 0·19 L. With a sample size of 40 participants per genotype, the actual eff ect size for detecting betweengenotype diff erences with respect to end-of-treatment morning PEF was 15 L/min, and the eff ect sizes for detecting treatment regimen diff erences within each genotype were 13·3 L/min for morning PEF and 0·13 L for FEV 1 .
Means (SDs) were calculated as descriptive statistics for baseline variables, apart from those variables with skewed distributions, for which medians or geometric means (IQR) were calculated. Paired t tests, Wilcoxon signed rank tests, and McNemar tests were applied, corresponding with the type of descriptive statistic, to compare genotypic groups with respect to baseline variables while accounting for matched pairs. Because of repeated measurements of primary and secondary response variables over time, we used longitudinal data analysis, incorporating all data from study participants.
For the primary outcome variable (morning PEF) and several of the secondary outcomes, we invoked a mixedeff ects linear model [13] [14] [15] that included an intercept and three slopes for the fi rst treatment period (study weeks 8-10, weeks 10-14, and weeks [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] and an intercept and three slopes for the second treatment period (study weeks 34-36, weeks 36-40, and weeks 40-52). Because we were mainly interested in the genotype-stratifi ed response to 18 weeks of treatment with salmeterol versus placebo, data from run-in and run-out periods were not included because treatment altered substantially when participants went from run-in to treatment period and from treatment to run-out period. Inclusion of either of these phases could artifi cially alter the longitudinal model, and not refl ect true treatmentrelated eff ects. Model parameters were estimated separately for each genotype and randomised drug sequence (ie, placebo followed by salmeterol or salmeterol followed by placebo). Outcome variables based on daily diary records were averaged over all of the days between clinic visits before data analysis. For most outcome variables, values were estimated from the model for the beginning and end of each treatment period, and appropriate contrasts comparing treatment regimens were calculated. Run-out data were modelled separately, fi tting an intercept and one slope for the fi rst run-out (study weeks 26-34) and an intercept and one slope for the second run-out period (study weeks 52-62). Diff erent model specifi cations were required for secondary outcome variables that were not obtained at all study visits (eg, methacholine PC 20 was obtained only at the beginning and end of each treatment period, allowing for estimation of only one treatment period slope). Use of rescue therapy and symptom score data showed scant variability, and values were generally very small (close to 0). Therefore, these outcome variables were analysed via Wilcoxon signed rank tests and Wilcoxon rank sum tests. Hodges-Lehmann estimates for the median paired diff erence (within genotype) and median diff erence (between genotypes) with 95% CIs are presented. 16 See webappendix p 1 for more detailed explanations of these statistical analyses.
PROC MIXED of the SAS/STAT statistical analysis software (version 9.1) was used for all longitudinal data analyses, with other SAS procedures for additional statistical analyses. S-plus was used to generate highlevel graphics. p values less than 0·05 were considered statistically signifi cant; no adjustment was made for analysis of multiple secondary outcomes.
As part of an intention-to-treat analysis, all available data on randomised participants were included in the statistical analysis, whether or not they had missed some visits, dropped out, or been non-compliant. An exception was made for three B16 Arg/Gly participants who were incorrectly categorised as Gly/Gly and initially randomised in the trial. Data for these three participants were removed from all reported analyses (action approved by the data and safety monitoring board). This trial is registered with ClinicalTrials.gov, number NCT00200967. 
Role of the funding sources
A protocol review committee appointed by the sponsor of the study approved the study design. A data and safety monitoring board appointed by the sponsor reviewed the fi nal manuscript. Neither group had any other role in the study. The companies providing the study drugs had no role in study design, data collection, data analysis, data inter preta tion, writing of the report, or in the decision to submit the report for publication. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication. Figure 2 shows the trial profi le. Between 2004 and 2006, 474 patients were screened for the trial. The B16 alleles were in Hardy-Weinberg equilibrium (p=0·95) in this population. 244 patients had eligible genotypes. Several of these patients (Arg/Arg, n=9; Gly/Gly, n=42) withdrew consent after screening because no appro priate match was identifi ed and they no longer wanted to participate in the pre-match protocol. 42 participants with the B16 Arg/Arg genotype and 45 with the B16 Gly/Gly genotype were randomly assigned to study treatment. Table 1 shows the demographic, clinical, and physiological characteristics of randomised participants at enrolment in the run-in period of the main study (after at least 3 weeks of standard inhaled corticosteroid therapy) by genotype. Matching participants by lung function was successful. Arg/Arg and Gly/Gly participants did not diff er signifi cantly at the beginning of each treatment period with respect to any measured baseline characteristic (data not shown).
Results
Of 1910 scheduled main study visits, 1901 (99·5%) were completed. During the double-blind treatment periods, participants recorded their morning PEF on a median of 95·7% (IQR 90·1-98·4) of days. Based on data from the DOSER and the Diskus devices, participants took 95·1% (90·1-97·9) of their scheduled inhaled corticosteroid puff s and 94·9% (88·2-98·6) of their scheduled salmeterol or placebo puff s.
After 18 weeks, mean morning PEF in Arg/Arg participants was 21·4 L/min (95% CI 11·8-31·1) greater when participants were assigned to receive salmeterol than when assigned to receive placebo (p<0·0001; table 2). Similarly, in Gly/Gly participants, morning PEF was 21·5 L/min (11·0-32·1) greater when participants were assigned to receive salmeterol than when they were assigned to receive placebo (p<0·0001). The diff erence between genotypes (the eff ect of treatment in Arg/Arg participants minus that in Gly/Gly participants) was -0·1 (-14·4 to 14·2; p=0·99; fi gure 3). Correspondingly, morning PEF in the run-out periods following treatment with salmeterol or placebo did not diff er signifi cantly (data not shown). Table 2 shows the analyses of the prespecifi ed secondary outcomes. There were within-genotype diff erences between the salmeterol and placebo treatments with respect to evening PEF, peak fl ow 
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Rescue ipratropium and salbutamol (puff s per day)|| (table 2) . In Gly/Gly participants, methacholine PC 20 was 2·4 times higher when participants were assigned to salmeterol than when assigned to placebo (p<0·0001); however, in Arg/Arg participants, methacholine PC 20 did not diff er between treatments (p=0·87; fi gure 4). The 2·5 times higher genotype-specifi c diff erence in responsive ness to methacholine was signifi cant (1·32 doubling dose diff erence between genotypes, 95% CI 0·43-2·21, p=0·0038; table 2); plots of individual participants are shown in fi gure 4 (and webappendix p 3). There were no genotype-specifi c diff erences for any other outcomes.
Both genotype groups had a fairly high degree of FEV 1 reversibility to four puff s of ipratropium (7·6-10·1%) and to four puff s of salbutamol (6·7-10·8%; table 2). There was no genotype-specifi c advantage for one bronchodilator over another. However, independent of genotype, the degree of bronchodilation with salbutamol was signifi cantly higher when participants were assigned to receive placebo than when assigned to receive salmeterol (Arg/Arg, p=0·001 and Gly/Gly, p=0·04; table 2). For both genotypes, response to ipra tro pium was similar for salmeterol and placebo treatments.
Seven Arg/Arg participants (placebo, n=5; salmeterol, n=2) and six Gly/Gly participants (placebo, n=3; salmeterol, n=3) had an exacerbation of asthma. No genotype-specifi c diff erences in exacerbation rates were seen. Five serious adverse events were reported: severe postoperative pain after loop electrosurgical excision procedure/cone biopsy for cervical dysplasia needing hospital stay (pre-match inhaled corticosteroid phase); hospital admission after scheduled outpatient surgery for repair of umbilical hernia (run-in inhaled corticosteroid phase); hospital admission for cellulitis of the right leg (double-blind treatment with salmeterol/ inhaled corticosteroid); hospital admission for bipolar disorder mood event (manic episode during doubleblind treatment with salmeterol/inhaled corticosteroid); and hospital admission for vaginal hysterectomy for treatment of abdominopelvic pain secondary to uterine fi broids (double-blind treatment with placebo/inhaled corticosteroid). None of the serious events was asthmarelated or related to study drugs or procedures. All participants recovered. The most prevalent non-serious adverse events reported were expected and respiratory in nature, with 94 events occurring during the pre-match/ run-in/run-out phases of the study, 74 occurring during double-blind treatment with placebo/inhaled corticosteroid, and 57 occurring during double-blind treatment with salmeterol/inhaled corticosteroid. Most events were acute nasopharyngitis and acute pharyngitis.
Results in white participants alone mirrored those of the entire study population. However, an exploratory post-hoc subgroup analysis in African-Americans showed that in the eight Gly/Gly participants, mean morning and evening PEF were 29 L/min and 45 L/min higher when participants were assigned to salmeterol than when assigned to placebo, respectively (p=0·013 and p=0·0005, respectively). Morning and evening PEF did not diff er between treatments in the nine participants with the Arg/Arg genotype (diff erence [salmeterolplacebo] -12 L/min, p=0·57 and -2·2 L/min, p=0·92, respectively; fi gure 5). Mean PEF measured at clinic visits during spirometry was also higher when participants were assigned to salmeterol than when assigned to placebo in African-American Gly/Gly participants (diff erence 39 L/min, p=0·0016) but not in Arg/Arg participants (-4·8 L/min, p=0·73). Although these subgroups were small, the genotype-specifi c diff erences in morning PEF (p=0·09) and evening PEF (p=0·07) approached signifi cance, while the diff erences in clinic-measured PEF reached signifi cance (p=0·02). Diff erences in responsiveness to methacholine paralleled the genotype-specifi c trend seen in the entire study cohort. There were only two Asian participants with the Arg/Arg genotype (only one of whom completed a phase of the trial), and one with the Gly/Gly genotype. Additionally, there were only four Hispanic Arg/Arg participants and fi ve Hispanic Gly/Gly participants. For such small groups, model-derived estimates could not be obtained. It is more appropriate to assess genotypespecifi c diff erences within ethnic groups if suffi cient numbers of participants are available for analysis.
There were no other signifi cant genotype-specifi c diff erences in other subgroups analysed, including in preplanned subanalyses of those who reversed by greater than or less than 12% with salbutamol, or in post-hoc subanalyses including only those who completed the entire trial, those who were on a controller within 6 weeks of study initiation, or men versus women (data not shown).
Discussion
Over the past decade, several studies have investigated the eff ect of specifi c mutations of the β-adrenergic receptor gene on response to β 2 agonists. 6, 7 A previous retrospective analysis of ACRN trials suggested that individuals with the ADRB2 B16 Arg/Arg genotype might not benefi t from treatment with longacting β 2 agonists, with or without inhaled corticosteroids. 8 However, in this prospective, randomised controlled trial, the addition of a longacting β 2 agonist to inhaled corticosteroid for 18 weeks produced similar improvements in airway function as shown by morning PEF in individuals with the B16 Arg/Arg and B16 Gly/Gly genotypes. Additionally, PEF did not decline during the run-out period, as has been seen in trials with shortacting β 2 agonists. 6, 17 These fi ndings are reassuring and accord with those from other retrospective studies that generally failed to show a B16 genotype-specifi c diff erence in PEF and asthma symptoms with combined use of longacting β 2 agonists and inhaled corticosteroids. 18, 19 A genotype-specifi c eff ect was noted in one of our prespecifi ed secondary outcome variables-metha choline PC 20 . The discrepant eff ects of longacting β 2 agonists on airway function compared with airway reactivity have been previously noted. 20 Furthermore, B16 Arg has been associated with greater decreases in bronchoprotection in response to regular use of a longacting β 2 agonist than has B16 Gly. 21 In all these cases, the bronchoprotective eff ect of the longacting β 2 agonist was assessed at 12 h or less after administra tion. Somewhat surprisingly, in our study, we found that salmeterol, when added to inhaled corticosteroid, enhanced bronchoprotection in B16 Gly/Gly participants (doubling dose shift in methacholine reactivity) but not in B16 Arg/Arg participants. This eff ect was unlikely to be caused by persistent bronchodilating eff ects of salmeterol, since the methacholine challenges were done after withholding salmeterol or placebo for 24 h. Some in-vitro data suggest that longacting β 2 agonists and inhaled corticosteroids produce synergistic eff ects through multiple molecular mechanisms (in- cluding facilitating the transcription of anti-infl ammatory genes and by acting as allosteric modulators, which might modify the conformation of glucocorticoid-bound glucocorticoid receptor or the binding of necessary cofactors and coactivators). 22, 23 Whether such interactions are aff ected by polymorphisms in ADRB2 and whether such a fi nding translates into increased effi cacy of the drug combination in patients with the Gly/Gly genotype are unclear. Another potential explanation for the observed diff erence relates to the fi nding that Arg/Arg human airway smooth muscle cells (as compared with Gly/Gly) can produce increased amounts of proinfl ammatory mediators in response to β 2 -agonist stimulation, 24 which might counteract the increased anti-infl ammatory eff ect of the β 2 -agonist/cortico steroid synergy.
In a post-hoc subanalysis of African-American individuals (20% of the cohort), we noted a genotypespecifi c diff erence in morning PEF (for both the mean daily home measurements and, separately, PEF measured at clinic visits) and in evening PEF. The Arg/ Arg group did not benefi t when salmeterol was added to inhaled corticosteroid, whereas the Gly/Gly group did; neither group had any adverse eff ects. Since our African-American subpopulation was small, this fi nding might be caused by beta error and should be considered exploratory; however, if confi rmed, this fi nding might have important implications. If AfricanAmerican individuals do not benefi t from the addition of longacting β 2 agonists to inhaled corticosteroids, they might be less likely to comply with such medications. Furthermore, a recent meta-analysis by the US Food and Drug Administration suggested an increased risk of serious adverse outcomes (combined deaths, intubations, and hospital admissions) with use of longacting β 2 agonists, especially in African-Americans. 25 Therefore, physicians might consider not treating African-Americans with the Arg/Arg genotype with longacting β 2 agonists in the context of a possible increase in serious adverse outcomes.
A recent prospective study in 475 African-Americans 26 found no signifi cant diff erence in the rate of asthma exacerbations when longacting β 2 agonist was added to inhaled corticosteroid and only a small diff erence in FEV 1 (3·5% between treatment groups despite the fact that to enter the study all patients needed to demonstrate a >12% improvement in FEV 1 while on inhaled corticosteroid). Furthermore, although there was a substantial reduction in nocturnal asthma, there was no diff erence in symptom scores, symptom-free days, salbutamol use, or salbutamolfree days between treatment groups. It is possible to speculate that the Arg/Arg participants (20% of AfricanAmericans) contributed to the small degree of improvement seen in this study. We used a moderately high dose of inhaled corticosteroid in this study (480 μg hydrofl uoroalkane beclometasone per day). It is unclear whether genotype-specifi c eff ects become evident at lower doses of inhaled corticosteroid often used in combination therapy. 18, 19 Additionally, it is important to distinguish our study of a longacting β 2 agonist from studies of shortacting β 2 agonists. Retrospective and prospective studies of shortacting β 2 agonists have shown genotype-specifi c eff ects on peak fl ow, drug use, asthma exacerbations, and asthma symptoms, [5] [6] [7] suggesting either that there is a diff erential response between shortacting and longacting β 2 agonists or that inhaled corticosteroid might prevent the detrimental response seen with shortacting β 2 agonists. Additionally, the Arg/Arg associations might not be causative. These polymorphisms might be in linkage disequilibrium with other polymorphisms that are, in fact, biologically important. Since our study was genotypestratifi ed, we could not assess whether haplotypic combinations of polymorphisms showed even greater associations than those we detected.
Thus, the LARGE study showed that B16 Arg/Arg and B16 Gly/Gly patients with asthma had similar and substantial improvements in airway function when salmeterol was added to inhaled corticosteroid therapy. These fi ndings provide reassurance that, in the general population, patients should continue to be treated with longacting β 2 agonists plus moderate-dose inhaled corticosteroids irrespective of B16 genotype. However, we need to further investigate the importance of the genotype-diff erentiated response in airway reactivity favouring Gly/Gly participants, as well as the fi nding that African-Americans with the the Arg/Arg genotype might not benefi t from treatment with salmeterol. 
